175 related articles for article (PubMed ID: 31084772)
21. Fluorodeoxyglucose positron emission tomography (FDG-PET) and PET/computed tomography imaging characteristics of thyroid lymphoma and their potential clinical utility.
Basu S; Li G; Bural G; Alavi A
Acta Radiol; 2009 Mar; 50(2):201-4. PubMed ID: 19089692
[TBL] [Abstract][Full Text] [Related]
22. The role of FDG-PET imaging in the management of lymphoma.
Kostakoglu L; Leonard JP; Coleman M; Goldsmith SJ
Clin Adv Hematol Oncol; 2004 Feb; 2(2):115-21. PubMed ID: 16163171
[TBL] [Abstract][Full Text] [Related]
23. Prognostic value of early 18 fluorodeoxyglucose positron emission tomography and gallium-67 scintigraphy in aggressive lymphoma: a prospective comparative study.
Fruchart C; Reman O; Le Stang N; Musafiri D; Cheze S; Macro M; Switsers O; Aide N; Liegard M; Levaltier X; Peny AM; Leporrier M; Bardet S
Leuk Lymphoma; 2006 Dec; 47(12):2547-57. PubMed ID: 17169799
[TBL] [Abstract][Full Text] [Related]
24. The impact of pre- and post-transplantation positron emission tomography using 18-fluorodeoxyglucose on poor-prognosis lymphoma patients undergoing autologous stem cell transplantation.
Filmont JE; Gisselbrecht C; Cuenca X; Deville L; Ertault M; Brice P; De Kerviler E; Briere J; Larghero J; Moretti JL; Mounier N
Cancer; 2007 Sep; 110(6):1361-9. PubMed ID: 17623832
[TBL] [Abstract][Full Text] [Related]
25. 2-[18F]fluoro-2-deoxyglucose positron-emission tomography in staging, response evaluation, and treatment planning of lymphomas.
Specht L
Semin Radiat Oncol; 2007 Jul; 17(3):190-7. PubMed ID: 17591566
[TBL] [Abstract][Full Text] [Related]
26. VI. FDG-PET as a biomarker in lymphoma: from qualitative to quantitative analysis.
Meignan M
Hematol Oncol; 2015 Jun; 33 Suppl 1():38-41. PubMed ID: 26062052
[No Abstract] [Full Text] [Related]
27. Integrating PET and PET/CT into the risk-adapted therapy of lymphoma.
Kasamon YL; Jones RJ; Wahl RL
J Nucl Med; 2007 Jan; 48 Suppl 1():19S-27S. PubMed ID: 17204717
[TBL] [Abstract][Full Text] [Related]
28. The impact of fluorodeoxyglucose-positron emission tomography in primary staging and patient management in lymphoma patients.
Allen-Auerbach M; de Vos S; Czernin J
Radiol Clin North Am; 2008 Mar; 46(2):199-211, vii. PubMed ID: 18619376
[TBL] [Abstract][Full Text] [Related]
29. [Application of 18F-FDG PET for the assessment of early response to the treatment and prognosis of patients].
Oriuchi N; Higuchi T; Endo K; Tsukamoto N; Matsuda H; Kuji I; Murakami K; Nakajima K
Kaku Igaku; 2009 Jun; 46(2):96-9. PubMed ID: 19637820
[TBL] [Abstract][Full Text] [Related]
30. PET/CT for therapy response assessment in lymphoma.
Hutchings M; Barrington SF
J Nucl Med; 2009 May; 50 Suppl 1():21S-30S. PubMed ID: 19380407
[TBL] [Abstract][Full Text] [Related]
31. Positron emission tomography with [(18)F]FDG for therapy response monitoring in lymphoma patients.
Spaepen K; Stroobants S; Verhoef G; Mortelmans L
Eur J Nucl Med Mol Imaging; 2003 Jun; 30 Suppl 1():S97-105. PubMed ID: 12709831
[TBL] [Abstract][Full Text] [Related]
32. FDG PET/CT versus CT, MR imaging, and 67Ga scintigraphy in the posttherapy evaluation of malignant lymphoma.
Okada M; Sato N; Ishii K; Matsumura K; Hosono M; Murakami T
Radiographics; 2010; 30(4):939-57. PubMed ID: 20631361
[TBL] [Abstract][Full Text] [Related]
33.
Ferdová E; Ferda J; Baxa J
Eur J Radiol; 2017 Sep; 94():A52-A63. PubMed ID: 28132716
[TBL] [Abstract][Full Text] [Related]
34. Utility of brain FDG-PET in primary CNS lymphoma.
Mohile NA; Deangelis LM; Abrey LE
Clin Adv Hematol Oncol; 2008 Nov; 6(11):818-20, 840. PubMed ID: 19194366
[TBL] [Abstract][Full Text] [Related]
35. PET and PET/CT in management of the lymphomas.
Podoloff DA; Macapinlac HA
Radiol Clin North Am; 2007 Jul; 45(4):689-96, vii. PubMed ID: 17706533
[TBL] [Abstract][Full Text] [Related]
36. Potential pitfalls of 18F-FDG PET in a large series of patients treated for malignant lymphoma: prevalence and scan interpretation.
Castellucci P; Nanni C; Farsad M; Alinari L; Zinzani P; Stefoni V; Battista G; Valentini D; Pettinato C; Marengo M; Boschi S; Canini R; Baccarani M; Monetti N; Franchi R; Rampin L; Fanti S; Rubello D
Nucl Med Commun; 2005 Aug; 26(8):689-94. PubMed ID: 16000986
[TBL] [Abstract][Full Text] [Related]
37. Positron emission tomography in the evaluation of lymphoma.
Israel O; Keidar Z; Bar-Shalom R
Semin Nucl Med; 2004 Jul; 34(3):166-79. PubMed ID: 15202099
[TBL] [Abstract][Full Text] [Related]
38. The evolving role of fluorodeoxyglucose positron emission tomography (FDG PET) in lymphoma: how do we reconcile conflicting results in the era of evidence-based medicine?
Hicks RJ
Leuk Lymphoma; 2006 Oct; 47(10):2008-10. PubMed ID: 17071468
[No Abstract] [Full Text] [Related]
39. (18)F-Flourodeoxy-Glucose PET/Computed Tomography in Brain Tumors: Value to Patient Management and Survival Outcomes.
Wray R; Solnes L; Mena E; Meoded A; Subramaniam RM
PET Clin; 2015 Jul; 10(3):423-30. PubMed ID: 26099676
[TBL] [Abstract][Full Text] [Related]
40. [18F-fluorodeoxyglucose positron emission tomography in the evaluation of therapy response assessment in lymphomas. Systematic literature review and meta-analysis].
Ramos-Font C; Rebollo Aguirre AC; Villegas Portero R; Romero Tabares A; Gallego Peinado M; Llamas Elvira JM
Rev Esp Med Nucl; 2009; 28(2):48-55. PubMed ID: 19406048
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
